Janssen further expands Schaffhausen site
Cilag AG is one of the most important employers in the Canton of Schaffhausen
It currently employs 1400 people - and aims to grow to over 1500 employees by the end of 2022. To enable the company to expand further, it is investing around 150 million Swiss francs over the next two years.
Cilag AG manufactures more than 20 pharmaceutical products at its site in the city of Schaffhausen. With currently 1400 employees, it is one of the most important employers in the Schaffhausen region. And on course for success. In the past two years, the company has grown by 150 employees, as outgoing CEO Kyran Johnson recently emphasised in an interview with the Schaffhauser Nachrichten. Johnson, who has headed the Schaffhausen site for the past three years, is taking over the Large Molecule platform management post in his native Ireland and will be responsible for several sites at once. Among them is the one in Schaffhausen.
He is reluctant to leave the canton of Schaffhausen. He loves Schaffhausen. The city and the landscape are beautiful, he says in the interview. Under Johnson's guidance, Cilag AG added three new drugs to its portfolio, two against cancer and one against HIV. The production portfolio in Schaffhausen is to be expanded to include new drugs. To this end, the parent company Johnson & Johnson is investing heavily in Schaffhausen. 150 million over the next two years. At the same time, it is planned that the number of employees will increase to over 1500 by the end of 2022.
"The location is very important for the parent company," Johnson emphasises in the interview. This is also because a lot of technical knowledge is available in the Schaffhausen workforce.
Cilag AG is part of the Johnson & Johnson Group and produces active pharmaceutical ingredients and products that are sold under the brand name Janssen. With about 1400 employees, the company is one of the largest producers in the pharmaceutical industry in Switzerland.
